{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:45:25Z","timestamp":1787316325128,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The purpose of this study was to examine trends in prescribing practices for individuals diagnosed with personality disorders (PD) over a 10-year period in a major metropolitan area in Sweden. Our aim was to assess the alignment of prescribing patterns with national clinical guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A register analysis was conducted on 26,520 pharmacological prescriptions from patients' Electronic Health Records (EHRs), documented between January 2011 and December 2020. The study compared the annual proportion of prescriptions across various psychotropic medication classes over time between individuals diagnosed with PD alone and those diagnosed with PD and co-occurring clinical conditions. Additionally, polypharmacy (\u2265\u20093 psychiatric medications) was investigated in both groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The proportion of individuals diagnosed with PD alone who received medication increased significantly over the study period. No significant changes were observed in polypharmacy, which remained prevalent in both groups. In the PD alone group, significant negative trends were observed in prescriptions for antidepressants, mood stabilizers, and benzodiazepine derivatives, while stimulant prescriptions rose significantly. In contrast, non-benzodiazepine sedatives and antipsychotics increased significantly in the group with co-occurring conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study indicates mixed adherence to Swedish national prescribing guidelines for PD. While there was alignment with recommendations, such as reduced benzodiazepine use, challenges remain in addressing polypharmacy and the prescribing of medications without clear indications, particularly in individuals without comorbidities. These findings emphasize the need for improved diagnostic accuracy, ongoing clinician education, and the integration of prescribing data with diagnostic and treatment records. Future research should explore prescribing practices across various clinical settings and assess the influence of psychopharmacological trends on prescribing, while also defining polypharmacy in the context of personality disorders to guide clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-025-06716-4","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T08:04:14Z","timestamp":1743581054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Trends in pharmacological prescriptions and polypharmacy for personality disorders: a 10-year cross-sectional analysis of naturalistic data"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2100-4006","authenticated-orcid":false,"given":"Flavio","family":"Di Leone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8320-5607","authenticated-orcid":false,"given":"Steinn","family":"Steingrimsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1656-9624","authenticated-orcid":false,"given":"Hanne Krage","family":"Carlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6505-9818","authenticated-orcid":false,"given":"Sophie I.","family":"Liljedahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4737-5670","authenticated-orcid":false,"given":"Peter","family":"Sand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"6716_CR1","unstructured":"Aiff, H. ed. (2024) [Psychopharmacology: Clinical Guidelines for Investigation and Treatment] Swedish psychiatric Association, Gothia F\u00f6rlag AB."},{"key":"6716_CR2","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association Practice Guideline for the Treatment of Patients With Borderline Personality Disorder (Second Edition). (2024). American Psychiatric Association Publishing. https:\/\/doi.org\/10.1176\/appi.books.9780890428009","DOI":"10.1176\/appi.books.9780890428009"},{"issue":"10 Suppl","key":"6716_CR3","first-page":"1","volume":"158","author":"American Psychiatric Association Practice Guidelines","year":"2001","unstructured":"American Psychiatric Association Practice Guidelines. Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry. 2001;158(10 Suppl):1\u201352.","journal-title":"Am J Psychiatry"},{"issue":"12","key":"6716_CR4","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1176\/appi.ajp.2009.09040539","volume":"166","author":"A Bateman","year":"2009","unstructured":"Bateman A, Fonagy P. Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Am J Psychiatry. 2009;166(12):1355\u201364. https:\/\/doi.org\/10.1176\/appi.ajp.2009.09040539.","journal-title":"Am J Psychiatry"},{"issue":"12","key":"6716_CR5","doi-asserted-by":"publisher","first-page":"009780","DOI":"10.1002\/14651858.CD009780.pub3","volume":"12","author":"I Bighelli","year":"2016","unstructured":"Bighelli I, Ostuzzi G, Girlanda F, Cipriani A, Becker T, Koesters M, Barbui C. Implementation of treatment guidelines for specialist mental health care. Coch Database System Rev. 2016;12(12):009780. https:\/\/doi.org\/10.1002\/14651858.CD009780.pub3.","journal-title":"Coch Database System Rev."},{"issue":"1","key":"6716_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/14656566.2019.1686482","volume":"21","author":"P Bozzatello","year":"2020","unstructured":"Bozzatello P, Rocca P, De Rosa ML, Bellino S. Current and emerging medications for borderline personality disorder: Is pharmacotherapy alone enough? Expert Opin Pharmacother. 2020;21(1):47\u201361. https:\/\/doi.org\/10.1080\/14656566.2019.1686482.","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"6716_CR7","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.euroneuro.2015.03.017","volume":"25","author":"R Bridler","year":"2015","unstructured":"Bridler R, H\u00e4berle A, M\u00fcller ST, et al. Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders. Eur Neuropsychopharmacol. 2015;25(6):763\u201372. https:\/\/doi.org\/10.1016\/j.euroneuro.2015.03.017.","journal-title":"Eur Neuropsychopharmacol"},{"key":"6716_CR8","volume-title":"Personality Disorders, Clinical Guidelines for Investigation and Treatment","year":"2017","unstructured":"Ekselius L, editor. Personality Disorders, Clinical Guidelines for Investigation and Treatment. Gothia F\u00f6rlag AB: Swedish psychiatric Association; 2017."},{"key":"6716_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbae098","author":"Y Furukawa","year":"2024","unstructured":"Furukawa Y, Imai K, Takahashi Y, Efthimiou O, Leucht S. Comparative Efficacy and Acceptability of Treatment Strategies for Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-analysis. Schizophrenia bulletin, Advance online publication. 2024. https:\/\/doi.org\/10.1093\/schbul\/sbae098.","journal-title":"Schizophrenia bulletin, Advance online publication"},{"issue":"10","key":"6716_CR10","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-021-00855-4","volume":"35","author":"G Gartlehner","year":"2021","unstructured":"Gartlehner G, Crotty K, Kennedy S, Edlund MJ, Ali R, Siddiqui M, Fortman R, Wines R, Persad E, Viswanathan M. Pharmacological treatments for borderline personality disorder: A systematic review and meta-analysis. CNS Drugs. 2021;35(10):1053\u201367. https:\/\/doi.org\/10.1007\/s40263-021-00855-4.","journal-title":"CNS Drugs"},{"key":"6716_CR11","doi-asserted-by":"crossref","unstructured":"Gartlehner, G., Crotty, K., Kennedy, S., Edlund, M. J., Ali, R., Siddiqui, M., ... & Viswanathan, M. (2021). Pharmacological treatments for borderline personality disorder: a systematic review and meta-analysis. CNS drugs, 1\u201315.","DOI":"10.1007\/s40263-021-00855-4"},{"issue":"8","key":"6716_CR12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1176\/appi.ajp.2018.18050576","volume":"175","author":"JG Gunderson","year":"2018","unstructured":"Gunderson JG, Choi-Kain LW. Medication management for patients with borderline personality disorder. Am J Psychiatry. 2018;175(8):709\u201311. https:\/\/doi.org\/10.1176\/appi.ajp.2018.18050576.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"6716_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/bcpt.13811","volume":"132","author":"M H\u00f8jlund","year":"2023","unstructured":"H\u00f8jlund M, Gudmundsson LS, Andersen JH, Saastamoinen LK, Zoega H, Skurtveit SO, Wastesson JW, Hallas J, Potteg\u00e5rd A. Use of benzodiazepines and benzodiazepine-related drugs in the Nordic countries between 2000 and 2020. Basic Clin Pharmacol Toxicol. 2023;132(1):60\u201370. https:\/\/doi.org\/10.1111\/bcpt.13811.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"6716_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/acps.12943","volume":"138","author":"MB J\u00f8rgensen","year":"2018","unstructured":"J\u00f8rgensen MB, Osler M. Should benzodiazepines be avoided? Acta Psychiatr Scand. 2018;138(2):89\u201390. https:\/\/doi.org\/10.1111\/acps.12943.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"6716_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/070674370905400306","volume":"54","author":"NJ Kolla","year":"2009","unstructured":"Kolla NJ, Links PS, McMain S, Streiner DL, Cardish R, Cook M. Demonstrating Adherence to Guidelines for the Treatment of Patients with Borderline Personality Disorder. The Canadian Journal of Psychiatry. 2009;54(3):181\u20139. https:\/\/doi.org\/10.1177\/070674370905400306.","journal-title":"The Canadian Journal of Psychiatry"},{"issue":"1","key":"6716_CR16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. https:\/\/doi.org\/10.1186\/s12877-017-0621-2.","journal-title":"BMC Geriatr"},{"key":"6716_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2019.112671","volume":"284","author":"T Nguyen","year":"2020","unstructured":"Nguyen T, Seiler N, Brown E, O\u2019Donoghue B. The effect of clinical practice guidelines on prescribing practice in mental health: A systematic review. Psychiatry Res. 2020;284: 112671. https:\/\/doi.org\/10.1016\/j.psychres.2019.112671.","journal-title":"Psychiatry Res"},{"issue":"9","key":"6716_CR18","doi-asserted-by":"publisher","first-page":"3769","DOI":"10.1007\/s10803-021-05411-z","volume":"52","author":"J Nyrenius","year":"2022","unstructured":"Nyrenius J, Eberhard J, Ghaziuddin M, Gillberg C, Billstedt E. Prevalence of Autism Spectrum Disorders in Adult Outpatient Psychiatry. J Autism Dev Disord. 2022;52(9):3769\u201379. https:\/\/doi.org\/10.1007\/s10803-021-05411-z.","journal-title":"J Autism Dev Disord"},{"issue":"1","key":"6716_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/13651501.2016.1235202","volume":"21","author":"E Paolini","year":"2017","unstructured":"Paolini E, Mezzetti FA, Pierri F, Moretti P. Pharmacological treatment of borderline personality disorder: A retrospective observational study at inpatient unit in Italy. Int J Psychiatry Clin Pract. 2017;21(1):75\u20139. https:\/\/doi.org\/10.1080\/13651501.2016.1235202.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"6","key":"6716_CR20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40263-023-01015-6","volume":"37","author":"JC Pascual","year":"2023","unstructured":"Pascual JC, Arias L, Soler J. Pharmacological management of borderline personality disorder and common comorbidities. CNS Drugs. 2023;37(6):489\u201397. https:\/\/doi.org\/10.1007\/s40263-023-01015-6.","journal-title":"CNS Drugs"},{"issue":"6","key":"6716_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/YIC.0b013e32833e23ed","volume":"25","author":"JC Pascual","year":"2010","unstructured":"Pascual JC, Mart\u00edn-Blanco A, Soler J. A naturalistic study of changes in pharmacological prescription for borderline personality disorder in clinical practice: From APA to NICE guidelines. Int Clin Psychopharmacol. 2010;25(6):349\u201355. https:\/\/doi.org\/10.1097\/YIC.0b013e32833e23ed.","journal-title":"Int Clin Psychopharmacol"},{"issue":"9","key":"6716_CR22","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s40263-021-00852-7","volume":"35","author":"JC Pascual","year":"2021","unstructured":"Pascual JC, Mart\u00edn-Blanco A, Soler J. Twenty-year trends in the psychopharmacological treatment of outpatients with borderline personality disorder: A cross-sectional naturalistic study in Spain. CNS Drugs. 2021;35(9):1023\u201332. https:\/\/doi.org\/10.1007\/s40263-021-00852-7.","journal-title":"CNS Drugs"},{"issue":"4","key":"6716_CR23","doi-asserted-by":"publisher","first-page":"e512","DOI":"10.4088\/JCP.14m09228","volume":"76","author":"C Paton","year":"2015","unstructured":"Paton C, Crawford MJ, Bhatti SF, Patel MX, Barnes TR. The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services. J Clin Psychiatry. 2015;76(4):e512\u20138. https:\/\/doi.org\/10.4088\/JCP.14m09228.","journal-title":"J Clin Psychiatry"},{"key":"6716_CR24","doi-asserted-by":"publisher","unstructured":"Pereira Ribeiro J, Juul S, Kongerslev MT, J\u00f8rgensen MS, V\u00f6llm BA, Edemann-Callesen H, Sales C, Schaug JP, Lieb K, Simonsen E, Stoffers-Winterling JM, Storeb\u00f8 OJ. (2024). Pharmacological interventions for co-occurring psychopathology in people with borderline personality disorder: secondary analysis of the Cochrane systematic review with meta-analyses. Brit J Psychiatry: J Ment Sci. 1\u201312. Advance online publication. https:\/\/doi.org\/10.1192\/bjp.2024.172","DOI":"10.1192\/bjp.2024.172"},{"key":"6716_CR25","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.2147\/NDT.S155838","volume":"14","author":"M Polyzoi","year":"2018","unstructured":"Polyzoi M, Ahnemark E, Medin E, Ginsberg Y. Estimated prevalence and incidence of diagnosed ADHD and health care utilization in adults in Sweden - a longitudinal population-based register study. Neuropsychiatr Dis Treat. 2018;14:1149\u201361. https:\/\/doi.org\/10.2147\/NDT.S155838.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"6716_CR26","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/13651501.2019.1576904","volume":"23","author":"F Riffer","year":"2019","unstructured":"Riffer F, Farkas M, Streibl L, Kaiser E, Sprung M. Psychopharmacological treatment of patients with borderline personality disorder: comparing data from routine clinical care with recommended guidelines. Int J Psychiatry Clin Pract. 2019;23(3):178\u201388. https:\/\/doi.org\/10.1080\/13651501.2019.1576904.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"3","key":"6716_CR27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1521\/pedi.2024.38.3.225","volume":"38","author":"P Sand","year":"2024","unstructured":"Sand P, Dervisoski E, Kollia S, Strand J, Di Leone F. Psychiatrists\u2019 Perspectives on Prescription Decisions for Patients With Personality Disorders. J Pers Disord. 2024;38(3):225\u201340. https:\/\/doi.org\/10.1521\/pedi.2024.38.3.225.","journal-title":"J Pers Disord"},{"key":"6716_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5708\/EJMH.19.2024.0016","volume":"19","author":"JE Schulkens","year":"2024","unstructured":"Schulkens JE, Verhey FR, Sobczak S. Features of Polypharmacy in Dutch Older Outpatients with Personality Disorders: A Cross-Sectional Study. European Journal of Mental Health. 2024;19:1\u201310.","journal-title":"European Journal of Mental Health"},{"issue":"1","key":"6716_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40501-021-00255-x","volume":"9","author":"R Shapiro-Thompson","year":"2022","unstructured":"Shapiro-Thompson R, Fineberg SK. The state of overmedication in borderline personality disorder: Interpersonal and structural factors. Current Treatment Options in Psychiatry. 2022;9(1):1\u201313. https:\/\/doi.org\/10.1007\/s40501-021-00255-x.","journal-title":"Current Treatment Options in Psychiatry"},{"key":"6716_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40479-019-0106-3","volume":"6","author":"S Simonsen","year":"2019","unstructured":"Simonsen S, Bateman A, Bohus M, et al. European guidelines for personality disorders: Past, present, and future. Borderline Personality Disorder and Emotion Dysregulation. 2019;6:9. https:\/\/doi.org\/10.1186\/s40479-019-0106-3.","journal-title":"Border Personal Dis Emot Dysregul"},{"issue":"4","key":"6716_CR31","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/acps.13403","volume":"145","author":"J Soler","year":"2022","unstructured":"Soler J, Casellas-Pujol E, Fern\u00e1ndez-Felipe I, Mart\u00edn-Blanco A, Almenta D, Pascual JC. \u201cSkills for pills\u201d: The dialectical-behavioural therapy skills training reduces polypharmacy in borderline personality disorder. Acta Psychiatr Scand. 2022;145(4):332\u201342.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"6716_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11096-022-01490-9","volume":"45","author":"D Stewart","year":"2023","unstructured":"Stewart D, Al Hail M, Al-Shaibi S, Hussain TA, Abdelkader NN, Pallivalapila A, Thomas B, El Kassem W, Hanssens Y, Nazar Z. A scoping review of theories used to investigate clinician adherence to clinical practice guidelines. Int J Clin Pharm. 2023;45(1):52\u201363. https:\/\/doi.org\/10.1007\/s11096-022-01490-9.","journal-title":"Int J Clin Pharm"},{"issue":"11","key":"6716_CR33","doi-asserted-by":"publisher","first-page":"CD012956","DOI":"10.1002\/14651858.CD012956.pub2","volume":"11","author":"JM Stoffers-Winterling","year":"2022","unstructured":"Stoffers-Winterling JM, Storeb\u00f8 OJ, Pereira Ribeiro J, Kongerslev MT, V\u00f6llm BA, Mattivi JT, Faltinsen E, Todorovac A, J\u00f8rgensen MS, Callesen HE, Sales CP, Schaug JP, Simonsen E, Lieb K. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev. 2022;11(11):CD012956. https:\/\/doi.org\/10.1002\/14651858.CD012956.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"6716_CR34","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2023.592","volume":"9","author":"M Tennant","year":"2023","unstructured":"Tennant M, Frampton C, Mulder R, Beaglehole B. Polypharmacy in the treatment of people diagnosed with borderline personality disorder: repeated cross-sectional study using New Zealand\u2019s national databases. BJPsych open. 2023;9(6):e200. https:\/\/doi.org\/10.1192\/bjo.2023.592.","journal-title":"BJPsych open"},{"key":"6716_CR35","doi-asserted-by":"publisher","unstructured":"Zavlis O, Fonagy P. (2024). Either all mental disorders are personality disorders or there are no personality disorders. OSF. https:\/\/doi.org\/10.31234\/osf.io\/4xpdg","DOI":"10.31234\/osf.io\/4xpdg"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06716-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-06716-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06716-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T08:04:44Z","timestamp":1743581084000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-025-06716-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6716"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-06716-4","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"21 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were reviewed and approved by Regional Ethical Review Board of Western Sweden (Diary Number: 2020\u201307105).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"314"}}